AR054710A1 - FORMULATION OF MUTED PROTEINS OF STAPHYLOCOCCAL ENTEROTOXIN C1 (SEC1) AND METHOD FOR FORMULATION - Google Patents
FORMULATION OF MUTED PROTEINS OF STAPHYLOCOCCAL ENTEROTOXIN C1 (SEC1) AND METHOD FOR FORMULATIONInfo
- Publication number
- AR054710A1 AR054710A1 ARP050105011A ARP050105011A AR054710A1 AR 054710 A1 AR054710 A1 AR 054710A1 AR P050105011 A ARP050105011 A AR P050105011A AR P050105011 A ARP050105011 A AR P050105011A AR 054710 A1 AR054710 A1 AR 054710A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulation
- sec1
- mutant protein
- mastitis
- effects
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 6
- 231100000655 enterotoxin Toxicity 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 102000008300 Mutant Proteins Human genes 0.000 abstract 3
- 108010021466 Mutant Proteins Proteins 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 241000283690 Bos taurus Species 0.000 abstract 2
- 101000882406 Staphylococcus aureus Enterotoxin type C-1 Proteins 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 235000013365 dairy product Nutrition 0.000 abstract 2
- 208000004396 mastitis Diseases 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 241000191967 Staphylococcus aureus Species 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- -1 fatty acid ester Chemical class 0.000 abstract 1
- 230000036737 immune function Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000008206 lipophilic material Substances 0.000 abstract 1
- 239000011859 microparticle Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Formulacion de una proteína mutante de SEC1, una toxina de Staphylococcus aureus, que presenta efectos en la prevencion, alivio de síntomas y tratamiento de la mastitis mediante una funcion inmune mejorada de las vacas lecheras lactantes y no lactantes, que comprende micropartículas solidas que contienen a la proteína mutante de SEC1 como ingrediente activo, un excipiente estabilizador de la proteína, un excipiente auxiliar a base de carbohidrato, y un material lipofílico, dispersados en un aceite biocompatible y/o en un compuesto a base de éster de ácido graso. La formulacion es capaz de lograr una administracion in vivo efectiva de una proteína mutante soluble en agua que constituye un ingrediente activo mientras que mantiene su actividad. Además, la formulacion presenta efectos terapéuticos en la prevencion y en el tratamiento de la mastitis mediante efectos de inmunpotenciacion debido a la capacidad superior de produccion de anticuerpos cuando se administra a vacas lecheras. Además, la formulacion se puede utilizar como prepararcion inyectable.Formulation of a mutant protein of SEC1, a Staphylococcus aureus toxin, which has effects on prevention, symptom relief and treatment of mastitis through enhanced immune function of lactating and non-lactating dairy cows, which comprises solid microparticles containing the mutant protein of SEC1 as an active ingredient, a protein stabilizing excipient, a carbohydrate-based auxiliary excipient, and a lipophilic material, dispersed in a biocompatible oil and / or in a fatty acid ester based compound. The formulation is capable of achieving an effective in vivo administration of a water soluble mutant protein that constitutes an active ingredient while maintaining its activity. In addition, the formulation has therapeutic effects in the prevention and treatment of mastitis through immunpotency effects due to the superior ability to produce antibodies when administered to dairy cows. In addition, the formulation can be used as an injectable preparation.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20040099624 | 2004-12-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054710A1 true AR054710A1 (en) | 2007-07-11 |
Family
ID=36565261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050105011A AR054710A1 (en) | 2004-12-01 | 2005-11-30 | FORMULATION OF MUTED PROTEINS OF STAPHYLOCOCCAL ENTEROTOXIN C1 (SEC1) AND METHOD FOR FORMULATION |
Country Status (5)
| Country | Link |
|---|---|
| KR (1) | KR100729954B1 (en) |
| AR (1) | AR054710A1 (en) |
| MY (1) | MY140503A (en) |
| PE (1) | PE20061171A1 (en) |
| WO (1) | WO2006059846A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2547361T1 (en) | 2010-03-17 | 2021-01-29 | SOCPRA - Sceiences et Genie, s.e.c. | Bacterial vaccine components from staphylococcus aureus and uses thereof |
| JP7181208B2 (en) | 2016-10-21 | 2022-11-30 | ソクプラ、サイエンシズ、エ、ジェニ、エス．イー．シー． | Vaccine constructs and their use against staphylococcal infections |
| KR102061735B1 (en) * | 2018-06-08 | 2020-01-02 | 대한민국(농림축산식품부 농림축산검역본부장) | A vaccine composition comprising recombinant protein of attenuated staphylococcal enterotoxin and cytotoxin |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100201352B1 (en) * | 1995-03-16 | 1999-06-15 | 성재갑 | Single injection vaccine formulation |
| DK1071407T3 (en) * | 1999-01-18 | 2014-10-20 | Lg Life Sciences Ltd | Lipophilic microparticles containing a protein drug or antigen and the same formulation |
| WO2001087270A2 (en) | 2000-05-12 | 2001-11-22 | Pharmacia & Upjohn Company | Vaccine composition, method of preparing the same, and method of vaccinating vertebrates |
-
2005
- 2005-11-16 WO PCT/KR2005/003871 patent/WO2006059846A1/en not_active Ceased
- 2005-11-16 KR KR1020050109644A patent/KR100729954B1/en not_active Expired - Fee Related
- 2005-11-18 PE PE2005001357A patent/PE20061171A1/en not_active Application Discontinuation
- 2005-11-29 MY MYPI20055582A patent/MY140503A/en unknown
- 2005-11-30 AR ARP050105011A patent/AR054710A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MY140503A (en) | 2009-12-31 |
| KR100729954B1 (en) | 2007-06-20 |
| PE20061171A1 (en) | 2006-12-18 |
| WO2006059846A1 (en) | 2006-06-08 |
| KR20060061225A (en) | 2006-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX395136B (en) | PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF ADMINISTRATION. | |
| TR201808178T4 (en) | Compositions for transdermal delivery of active agents. | |
| PT109395B (en) | PARASITICIDAL ORAL VETERINARY COMPOSITIONS UNDERSTANDING ACTIVE SYSTEMIC ACTING AGENTS, METHODS AND THEIR USES | |
| TR200003158T2 (en) | Gelling pharmaceutical compositions | |
| ATE332138T1 (en) | FLIBANSERIN FOR THE TREATMENT OF EXTRAPYRAMIDAL MOTION DISORDERS | |
| BR0114799A (en) | Cyanophenoxy carboxylic acid compounds and compositions for releasing active agents | |
| BRPI0512311A (en) | use of meloxicam in veterinary medicine for the treatment of painful inflammatory diseases | |
| EA201101706A1 (en) | Drug medication based on diyndolylmethanum (DIM) with enhanced bioavailability and its use in the treatment of hyperplastic and inflammatory diseases | |
| JP2016539921A5 (en) | ||
| EP1852114A4 (en) | PREPARATION CONTAINING DIHOMO- (gamma) -LINOLENIC ACID (DGLA) AS ACTIVE INGREDIENT | |
| EA201270615A1 (en) | ANTIGROUSE PREPARATION CONTAINING FUNGAL ORGANISM | |
| BRPI0510449A (en) | use of meloxicam formulations in veterinary medicine | |
| AR049518A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING A SILICONE AGENT AND TWO SOLUBILIZED ACTIVE PRINCIPLES | |
| EA200800360A1 (en) | FORMS WITH HIGH CONTENT OF DRUGS AND DOSED FORMS | |
| KR20130044330A (en) | Compositions for controlling heartworm infestation | |
| TW200600121A (en) | Pharmaceutical dosage forms | |
| RU2414221C2 (en) | Cyclopherone-based pharmaceutical composition of local or external application for treatment of purulent-destructive affection of mucous membrane and skin, general-system diseases in case of immunodeficiency conditions (versions) | |
| AR054710A1 (en) | FORMULATION OF MUTED PROTEINS OF STAPHYLOCOCCAL ENTEROTOXIN C1 (SEC1) AND METHOD FOR FORMULATION | |
| EP2982369A1 (en) | Preparation for treating equine inflammation | |
| FR2887150B1 (en) | PHARMACEUTICAL COMPOSITION COMPRISING AN ORGANOPOLYSILOXANE ELASTOMER AND A SOLUBILIZED ACTIVE INGREDIENT | |
| JP2010534221A (en) | Topical antibiotic composition for prevention of Lyme disease | |
| MX2023010847A (en) | Tasipimidine formulations and use thereof. | |
| ATE457721T1 (en) | PHARMACEUTICAL FORMULATIONS CONTAINING PHARMACEUTICAL ACTIVE INGREDIENTS ABSORBED ON TITANIUM DIOXIDE DNANOPARTICLES | |
| Mishra | An investigation on the approach to target lipopolysaccharide through polymeric capped nano-structured formulation for the management of sepsis | |
| Chhabra et al. | Sarcoptic mange in domestic animals and human scabies in India |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FA | Abandonment or withdrawal |